LONDON - LivaNova PLC (NASDAQ:LIVN), a prominent medical technology company, has announced the appointment of Vladimir A. Makatsaria as Chief Executive Officer (CEO) and a member of its Board of Directors, effective March 1, 2024. Makatsaria, who previously held the position of Company Group Chairman at Johnson & Johnson MedTech, brings extensive experience from his time leading the global Ethicon surgery business.
The transition comes as William Kozy, who has been serving as Interim CEO since April 2023, will continue to fulfill his role as the Board Chair of LivaNova. Kozy expressed the Board's strong confidence in Makatsaria's capabilities to propel the company's strategic plan forward and to stimulate long-term growth.
Makatsaria's career spans nearly three decades in the healthcare sector, with a focus on executive leadership within various technologies and geographical markets. His previous roles include Chairman of the Asia Pacific Medical Technology Association (APACMed) and Advisory Board Member at Singapore Management University. He holds academic qualifications in Physiology, Healthcare Administration, and Business Administration from the University of Minnesota.
In his statement, Makatsaria conveyed his eagerness to collaborate with LivaNova's global team, saying, "I look forward to working with the global team to deliver meaningful medical technologies to the patients we serve and to achieve LivaNova™s full potential."
LivaNova, headquartered in London, operates with a workforce of approximately 2,900 employees and maintains a presence in over 100 countries. The company focuses on developing medical technologies that significantly improve the lives of patients dealing with head and heart conditions.
The information in this article is based on a press release.
InvestingPro Insights
As LivaNova PLC welcomes Vladimir A. Makatsaria as its new CEO, the company is poised for a year of anticipated growth. InvestingPro data shows a market capitalization of $2.64 billion, with a notable revenue increase of 9.96% over the last twelve months as of Q3 2023. This financial health is underlined by a strong gross profit margin of 67.43%, reflecting the company’s ability to maintain profitability in its operations.
InvestingPro Tips suggest that LivaNova is expected to see net income growth this year, a promising sign for investors looking for potential growth opportunities. Moreover, the company's liquid assets surpass its short-term obligations, indicating a solid financial position for handling near-term liabilities. However, potential investors should be aware of the high earnings multiple, with an adjusted P/E ratio of 93.37 as of the last twelve months, which may suggest a premium market valuation.
For those considering an investment in LivaNova, additional insights are available. InvestingPro+ offers a wealth of further tips, with a current total of seven additional tips for LivaNova, providing a deeper dive into the company's financial nuances. To access these insights, consider taking advantage of the InvestingPro subscription, now on a special New Year sale with discounts of up to 50%. Moreover, use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.